✦ LIBER ✦
9013 POSTER DISCUSSION Phase I Dose-escalation Study of AXL1717: a Novel Targeted Oral Insulin-like Growth Factor-1 Receptor (IGF-1R) Inhibitor and Its Implications for Patients With Non-small Cell Lung Carcinoma
✍ Scribed by Ekman, S.; Harmenberg, J.; Stáhl, B.; Hedlund, A.; Bergström, S.; Frodin, J.; Bergqvist, M.
- Book ID
- 123335889
- Publisher
- Elsevier Science
- Year
- 2011
- Tongue
- English
- Weight
- 60 KB
- Volume
- 47
- Category
- Article
- ISSN
- 0959-8049
No coin nor oath required. For personal study only.